Review



bix02189 group  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress bix02189 group
    Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor <t>BIX02189.</t> Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]
    Bix02189 Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bix02189 group/product/MedChemExpress
    Average 94 stars, based on 15 article reviews
    bix02189 group - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5 /Mer signaling pathway"

    Article Title: Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5 /Mer signaling pathway

    Journal: FEBS Open Bio

    doi: 10.1002/2211-5463.13461

    Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor BIX02189. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]
    Figure Legend Snippet: Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor BIX02189. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Techniques Used: Expressing, Western Blot, Immunofluorescence, Membrane, Standard Deviation

    Ulinastatin enhanced macrophage efferocytosis and ameliorated LPS‐induced inflammatory injury. (A) Effect of UTI on phagocytosis and apoptosis of HL60 cells by RAW264.7 cells after using BIX02189. Left panel shows representative fluorescence images of HL60 phagocytic apoptosis in RAW264.7 cells. Scale, 100 μm; (B) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs after use of BIX02189. Representative images of apoptotic PMNs from alveolar macrophage phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (C) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of BIX02189, scale: 200 μm; (D) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs with XMD8‐92. Representative images of apoptotic PMNs from alveolar macrophages phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (E) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of XMD8‐92, scale: 200 μm; (F) Phagocytosis index (BIX02189) based on fluorescence images. (G) Phagocytosis index (BIX02189) based on representative images. (H) H&E staining was used to assess the pathological score (BIX02189). (I) Phagocytosis index (XMD8‐92) based on representative images. (J) H&E staining was used to assess the pathological score (XMD8‐92). Data are presented as mean ± standard deviation, one‐way ANOVA, n = 3. * P < 0.05 vs. UTI + LPS group or 5000 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]
    Figure Legend Snippet: Ulinastatin enhanced macrophage efferocytosis and ameliorated LPS‐induced inflammatory injury. (A) Effect of UTI on phagocytosis and apoptosis of HL60 cells by RAW264.7 cells after using BIX02189. Left panel shows representative fluorescence images of HL60 phagocytic apoptosis in RAW264.7 cells. Scale, 100 μm; (B) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs after use of BIX02189. Representative images of apoptotic PMNs from alveolar macrophage phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (C) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of BIX02189, scale: 200 μm; (D) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs with XMD8‐92. Representative images of apoptotic PMNs from alveolar macrophages phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (E) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of XMD8‐92, scale: 200 μm; (F) Phagocytosis index (BIX02189) based on fluorescence images. (G) Phagocytosis index (BIX02189) based on representative images. (H) H&E staining was used to assess the pathological score (BIX02189). (I) Phagocytosis index (XMD8‐92) based on representative images. (J) H&E staining was used to assess the pathological score (XMD8‐92). Data are presented as mean ± standard deviation, one‐way ANOVA, n = 3. * P < 0.05 vs. UTI + LPS group or 5000 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Techniques Used: Fluorescence, Staining, Standard Deviation



    Similar Products

    bix02189 group  (MedChemExpress)
    94
    MedChemExpress bix02189 group
    Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor <t>BIX02189.</t> Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]
    Bix02189 Group, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bix02189 group/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    bix02189 group - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor BIX02189. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Journal: FEBS Open Bio

    Article Title: Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5 /Mer signaling pathway

    doi: 10.1002/2211-5463.13461

    Figure Lengend Snippet: Ulinastatin upregulated Mer expression by activating ERK5. (A) ERK5 and p‐ERK5 protein levels were detected by Western blotting. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (B) ERK5 and p‐ERK5 protein levels were determined by Western blotting after treatment with inhibitor BIX02189. Upper part: Representative blot of protein expression; lower part: Relative protein expression of ERK5 and p‐ERK5. (C) ERK5 protein levels were determined by Western blotting after treatment with the inhibitor XMD8‐92. Left: Representative blot of protein expression; right: Relative protein expression of ERK5 and p‐ERK5. (D) Immunofluorescence assay for the determination of membrane protein Mer after treatment with the inhibitor BIX02189. (E) Relative protein expression of membrane protein Mer. (F) The level of membrane protein Mer was determined by immunofluorescence assay after treatment with the inhibitor XMD8‐92. (G) Relative protein expression of membrane protein Mer. Data is expressed as mean ± standard deviation, one‐way ANOVA, n = 3, * P < 0.05 vs. 0 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Article Snippet: After cell adherence, the cells were pretreated with ulinastatin at different concentrations for 3 h. ERK5 inhibitor BIX02189 (MedChemExpress, HY‐12056) was used to divide the cells into blank control group, BIX02189 group, 5000 U·mL −1 group, and 5000 U·mL −1 + BIX02189 group.

    Techniques: Expressing, Western Blot, Immunofluorescence, Membrane, Standard Deviation

    Ulinastatin enhanced macrophage efferocytosis and ameliorated LPS‐induced inflammatory injury. (A) Effect of UTI on phagocytosis and apoptosis of HL60 cells by RAW264.7 cells after using BIX02189. Left panel shows representative fluorescence images of HL60 phagocytic apoptosis in RAW264.7 cells. Scale, 100 μm; (B) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs after use of BIX02189. Representative images of apoptotic PMNs from alveolar macrophage phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (C) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of BIX02189, scale: 200 μm; (D) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs with XMD8‐92. Representative images of apoptotic PMNs from alveolar macrophages phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (E) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of XMD8‐92, scale: 200 μm; (F) Phagocytosis index (BIX02189) based on fluorescence images. (G) Phagocytosis index (BIX02189) based on representative images. (H) H&E staining was used to assess the pathological score (BIX02189). (I) Phagocytosis index (XMD8‐92) based on representative images. (J) H&E staining was used to assess the pathological score (XMD8‐92). Data are presented as mean ± standard deviation, one‐way ANOVA, n = 3. * P < 0.05 vs. UTI + LPS group or 5000 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Journal: FEBS Open Bio

    Article Title: Ulinastatin promotes macrophage efferocytosis and ameliorates lung inflammation via the ERK5 /Mer signaling pathway

    doi: 10.1002/2211-5463.13461

    Figure Lengend Snippet: Ulinastatin enhanced macrophage efferocytosis and ameliorated LPS‐induced inflammatory injury. (A) Effect of UTI on phagocytosis and apoptosis of HL60 cells by RAW264.7 cells after using BIX02189. Left panel shows representative fluorescence images of HL60 phagocytic apoptosis in RAW264.7 cells. Scale, 100 μm; (B) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs after use of BIX02189. Representative images of apoptotic PMNs from alveolar macrophage phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (C) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of BIX02189, scale: 200 μm; (D) UTI enhanced the ability of alveolar macrophage to phagocytose apoptotic PMNs with XMD8‐92. Representative images of apoptotic PMNs from alveolar macrophages phagocytizing cells, scale:100 μm; arrows indicate macrophages containing apoptotic bodies. (E) Hematoxylin and eosin (H&E) staining of mouse lung tissue after use of XMD8‐92, scale: 200 μm; (F) Phagocytosis index (BIX02189) based on fluorescence images. (G) Phagocytosis index (BIX02189) based on representative images. (H) H&E staining was used to assess the pathological score (BIX02189). (I) Phagocytosis index (XMD8‐92) based on representative images. (J) H&E staining was used to assess the pathological score (XMD8‐92). Data are presented as mean ± standard deviation, one‐way ANOVA, n = 3. * P < 0.05 vs. UTI + LPS group or 5000 U·mL −1 UTI group. [Colour figure can be viewed at wileyonlinelibrary.com ]

    Article Snippet: After cell adherence, the cells were pretreated with ulinastatin at different concentrations for 3 h. ERK5 inhibitor BIX02189 (MedChemExpress, HY‐12056) was used to divide the cells into blank control group, BIX02189 group, 5000 U·mL −1 group, and 5000 U·mL −1 + BIX02189 group.

    Techniques: Fluorescence, Staining, Standard Deviation